Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic Hepatitis B Age: Adults and adolescents greater than or equal to 16 years Condition: Nucleoside inhibitor treatment-naive with compensated liver disease |
Dose: Tablet – 0.5 mg Frequency: once daily Note: Administered by mouth. Indicated for treatment of CHB with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. |
|
Indication: Chronic Hepatitis B Age: Adults and adolescents greater than or equal to 16 years Condition: Lamivudine-refractory or known lamivudine or telbivudine resistance substitutions |
Dose: Tablet – 1 mg Frequency: once daily Note: Administered by mouth. Indicated for treatment of CHB with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic Hepatitis B Age: greater than or equal to 2 years Condition: evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease |
Dose: Not specified Note: Safety and efficacy not established in children less than 2 years |
|
Indication: Chronic Hepatitis B Age: greater than 16 years Condition: evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease |
Dose: Not specified Note: Dosed as adult |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Usual daily dose (0.5 mg) CrCl greater than or equal to 50 mL/min Condition: Renal Impairment |
Dose: Tablet – 0.5 mg Note: No dosage adjustment required |
|
Indication: Usual daily dose (0.5 mg) CrCl 30-49 mL/min Condition: Renal Impairment |
Dose: Tablet – 0.25 mg Frequency: once daily Note: Or 0.5 mg every 48 hours |
Administration
- Take on empty stomach
- Take 2 hours before or after meals
Side Effect
- Fatigue (1-3%)
- Headache (2-4%)
- Dizziness
- Nausea
- Diarrhea
- Dyspepsia
- Vomiting
- Somnolence
- Insomnia
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Drugs that reduce renal function or compete for active tubular secretion
|
May increase serum concentration of either entecavir or co-administered drug
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at temperatures not above 30°C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.